These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9426090)

  • 21. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.
    MacManus MP; Hicks RJ; Matthews JP; Hogg A; McKenzie AF; Wirth A; Ware RE; Ball DL
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):287-93. PubMed ID: 11380213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of non-small-cell lung cancer staging by means of positron emission tomography.
    Albes JM; Lietzenmayer R; Schott U; Schülen E; Wehrmann M; Ziemer G
    Thorac Cardiovasc Surg; 1999 Feb; 47(1):42-7. PubMed ID: 10218620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging with F-18 FDG PET is superior to Tl-201 SPECT in the staging of non-small cell lung cancer for radical radiation therapy.
    MacManus MP; Hicks RJ; Ball DL; Ciavarella F; Binns D; Hogg A; Kalff V; Ware R; Wirth A; Salminen E; McKenzie A
    Australas Radiol; 2001 Nov; 45(4):483-90. PubMed ID: 11903182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of positron emission tomography in staging esophageal cancer.
    Luketich JD; Schauer PR; Meltzer CC; Landreneau RJ; Urso GK; Townsend DW; Ferson PF; Keenan RJ; Belani CP
    Ann Thorac Surg; 1997 Sep; 64(3):765-9. PubMed ID: 9307471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT; Viswanathan C; Erasmus JJ
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.
    Kahn D; Menda Y; Kernstine K; Bushnell D; McLaughlin K; Miller S; Berbaum K
    Chest; 2004 Feb; 125(2):494-501. PubMed ID: 14769730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of scalene lymph node metastases from lung cancer. Positron emission tomography.
    Scott WJ; Gobar LS; Hauser LG; Sunderland JJ; Dewan NA; Sugimoto JT
    Chest; 1995 Apr; 107(4):1174-6. PubMed ID: 7705136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer: a multicenter study.
    Li X; Zhang H; Xing L; Ma H; Xie P; Zhang L; Xu X; Yue J; Sun X; Hu X; Chen M; Xu W; Chen L; Yu J
    Radiother Oncol; 2012 Feb; 102(2):246-50. PubMed ID: 22100657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer.
    Lewis P; Griffin S; Marsden P; Gee T; Nunan T; Malsey M; Dussek J
    Lancet; 1994 Nov; 344(8932):1265-6. PubMed ID: 7967988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung Cancer Group.
    Vansteenkiste JF; Stroobants SG; De Leyn PR; Dupont PJ; Verschakelen JA; Nackaerts KL; Mortelmans LA
    Chest; 1997 Dec; 112(6):1480-6. PubMed ID: 9404742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
    Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
    Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of 18F-fluorodeoxyglucose positron emission tomography imaging in staging of non-small cell lung cancer].
    Guan Y; He S; Dong J
    Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1180-3. PubMed ID: 11769705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
    Guhlmann A; Storck M; Kotzerke J; Moog F; Sunder-Plassmann L; Reske SN
    Thorax; 1997 May; 52(5):438-41. PubMed ID: 9176535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET: advantages for staging the mediastinum?
    Franzius C
    Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.